Methods of treating psoriasis with secukinumab

ChangeBridge: Patent Grants - Pharma (A61K)

Published April 7th, 2026

Detected April 7th, 2026

Summary

The USPTO granted Patent US12594331B2 to Novartis AG on April 7, 2026, covering methods of treating psoriasis using secukinumab, an IL-17 antagonist antibody. The patent contains 16 claims directed to therapeutic regimens employing the drug for psoriasis treatment. This grant provides Novartis with exclusive intellectual property rights over this specific treatment methodology in the United States.

View original document View source feed page

What changed

USPTO granted Patent US12594331B2 to Novartis AG for methods of treating psoriasis using secukinumab, an IL-17 antibody antagonist. The patent covers therapeutic regimens employing a therapeutically effective amount of secukinumab for psoriasis treatment.

For pharmaceutical companies developing biologics or biosimilars for autoimmune conditions, this patent establishes enforceable IP barriers for IL-17 antagonist-based psoriasis treatments. Competitors seeking to develop similar treatment methods must consider this patent in their freedom-to-operate analysis. Healthcare providers and patients are not directly affected by this IP grant.

What to do next

Monitor for updates
Review freedom-to-operate considerations if developing competing psoriasis treatments

Source document (simplified)

← USPTO Patent Grants

Methods of treating psoriasis with secukinumab

Grant US12594331B2 Kind: B2 Apr 07, 2026

Assignee

NOVARTIS AG

Inventors

Achim Guettner, Matthias Machacek, Charis Papavassilis, Oliver Sander

Abstract

The disclosure relates to novel regimens for treating psoriasis, which employ a therapeutically effective amount of an IL-17 antagonist, e.g. an IL-17 binding molecule, e.g., an IL-17 antibody, such as the secukinumab antibody, or an IL-17 receptor binding molecule, e.g., an IL-17 receptor antibody.